ReviewCurrent rheumatology reports2024
Multimorbidity in Rheumatoid Arthritis: Literature Review and Future Directions.
Review in Current rheumatology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review and meta-analysis of the efficacy and safety of iguratimod in the treatment of inflammatory arthritis and degenerative arthritis.Frontiers in pharmacology · 2024Pooled it
- Longitudinal changes in patient characteristics as drivers of clinical outcomes in the Early Undifferentiated PolyArthritis (EUPA) cohort.Rheumatology (Oxford, England) · 2026Trial
- Physical function in older people with rheumatoid arthritis and population controls: a cross-sectional study of self-reported and performance-based measures.Rheumatology international · 2026Article
- Bridging Population Patterns and Individual Prediction: Framework for Prospective Multimorbidity Study.JMIR medical informatics · 2026Article
- Associations of physical, psychological, and cognitive multimorbidity with health service utilisation and catastrophic health expenditure among middle-aged and older adults: a longitudinal study in China.Archives of public health = Archives belges de sante publique · 2026Article
- Central Sensitization and Nociplastic Pain: Shared Mechanisms in Fibromyalgia, Osteoarthritis, and Inflammatory Arthritis.Journal of pain research · 2026Review
- From arthritis to erectile dysfunction: potential pathophysiological mechanisms and multidisciplinary integrated management.Frontiers in cell and developmental biology · 2026Review
- Plasma metabolomic and lipidomic signatures characteristic of treatment non-response in rheumatoid arthritis.Frontiers in immunology · 2026Article
- Rheumatoid arthritis: a comprehensive overview of genetic markers, emerging therapies, and personalized medicine.Annals of medicine and surgery (2012) · 2025Review
- Current application, possibilities, and challenges of artificial intelligence in the management of rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis.Therapeutic advances in musculoskeletal disease · 2025Review
- The absolute number of circulating Treg cells is reduced in difficult-to-treat RA patients and is ameliorated by low-dose IL-2.Frontiers in immunology · 2025Article
- Predicting arthritis risk with machine learning: Insights from the 2023 National Health Interview Survey data.PloS one · 2025Article
- Management strategies in rheumatoid arthritis.Nature reviews. Rheumatology · 2024Review
- Advancing Rheumatology Care Through Machine Learning.Pharmaceutical medicine · 2024Article
- The emerging role of neutrophil extracellular traps in the progression of rheumatoid arthritis.Frontiers in immunology · 2024Review
- Association of advanced lung cancer inflammation index with all-cause and cardiovascular mortality in US patients with rheumatoid arthritis.Frontiers in nutrition · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purpose of reviewTo offer a narrative review of literature and an update on rheumatoid arthritis (RA) multimorbidity research over the past five years as well as future directions. RECENT
findingsPatients with RA experience higher prevalence of multimorbidity (31-86% vs 18-71% in non-RA) and faster accumulation of comorbidities. Patients with multimorbidity have worse outcomes compared to non-RA multimorbid patients and RA without multimorbidity including mortality, cardiac events, and hospitalizations. Comorbid disease clusters often included: cardiopulmonary, cardiometabolic, and depression and pain-related conditions. High-frequency comorbidities included interstitial lung disease, asthma, chronic obstructive pulmonary disease, cardiovascular disease, fibromyalgia, osteoarthritis, and osteoporosis, thyroid disorders, hypertension, and cancer. Furthermore, patients with RA and multimorbidity are paradoxically at increased risk of high RA disease activity but experience a lower likelihood of biologic use and more biologic failures. RA patients experience higher prevalence of multimorbidity and worse outcomes versus non-RA and RA without multimorbidity. Findings call for further studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.